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MaFractional ﬂow reserve derived from coronary computed tomography angiography enables noninvasive assessment of the
hemodynamic signiﬁcance of coronary artery lesions and coupling of the anatomic severity of a coronary stenosis with its
physiological effects. Since its initial demonstration of feasibility of use in humans in 2011, a signiﬁcant body of clinical
evidence has developed to evaluate the diagnostic performance of coronary computed tomography angiography–derived
fractional ﬂow reserve compared with an invasive fractional ﬂow reserve reference standard. The purpose of this paper
was to describe the scientiﬁc principles and to review the clinical data of this technology recently approved by the U.S.
Food and Drug Administration. (J Am Coll Cardiol Img 2015;8:1209–22) © 2015 by the American College of Cardiology
Foundation.STRENGTHS AND LIMITATIONS OF CURRENT
METHODS OF NONINVASIVE CORONARY
ARTERY DISEASE IMAGINGF or several decades, stress testing has servedas the cornerstone for assessment of symp-tomatic individuals with suspected or known
coronary artery disease (CAD) (1). When stress
testing is performed in conjunction with noninva-
sive imaging, an array of methods are used,
including stress echocardiography and myocardial
perfusion imaging (MPI) by single-photon emission
computed tomography (SPECT), positron emission
tomography, and cardiac magnetic resonance. These
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these methods, MPI by SPECT remains the most
commonly used technique for noninvasive CAD
evaluation in the United States, and it accounts
for approximately three-fourths of the 10 million
stress imaging tests performed in the United States
annually.
The rationale for the use of CFR for diagnosing CAD
stems from the pioneering research of Gould and
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with progressive narrowing of the coronary luminal
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ABBR EV I A T I ON S
AND ACRONYMS
AUC = area under the receiver-
operating characteristic curve
CABG = coronary artery bypass
graft
CAD = coronary artery disease
CFD = computational ﬂuid
dynamics
CFR = coronary ﬂow reserve
CT = computed tomography
CTA = computed tomography
angiography
FFR = fractional ﬂow reserve
FFRCT = coronary computed
tomography angiography–
derived fractional ﬂow reserve
MPI = myocardial perfusion
imaging
OMT = optimal medical therapy
PCI = percutaneous coronary
intervention
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1210(an inadequacy of myocardial oxygen for a
given metabolic state) and has never been
validated in a human model. Although re-
ductions in CFR manifest generally predict-
able reductions at hyperemic ﬂow states
for coronary stenosis $70%, the relationship
between coronary stenosis and myocardial
ischemia is nevertheless complex. Approxi-
mately 1 in 5 high-grade lesions with $70%
stenosis do not cause ischemia, and diminu-
tion of coronary ﬂow can begin as early as
40% diameter stenosis or in the context of
diffuse or serial “nonobstructive” stenosis
(5). Furthermore, CFR accounts for abnor-
malities across the entirety of the coronary
vascular bed, which includes not only the
epicardial coronary arteries but also the in-
tramyocardial pre-arteriolar, arteriolar, and
capillary circulations (6). Precise localization
of CFR abnormalities to the epicardial versus
nonepicardial vessels is vital, given that effec-
tive treatments exist for the former (includingboth medical therapy and revascularization), but no
knowneffective treatments exist for the latter.
Recent clinical data have assessed the diagnostic
speciﬁcity of MPI for patients undergoing invasive
coronary angiography (ICA). In the nuclear substudy
of the COURAGE (Clinical Outcomes Utilizing
Revascularization and Aggressive Drug Evaluation)
trial, only 32% of patients with $70% stenosis
exhibited severe ischemia and 40% manifested
no or mild ischemia according to MPI (7). Similarly,
among >650,000 patients undergoing nonemergent
ICA recorded in the National Cardiovascular Data
Registry, noninvasive stress test ﬁndings offered
minimal discriminatory value for identifying and
excluding anatomically “obstructive” coronary ste-
nosis (C index 0.75 vs. 0.74 for clinical evaluation
vs. noninvasive testing) (8). Similar ﬁndings were
observed in a 47-center study in Michigan: among
6,198 patients, stress imaging test results were not
predictive of high-grade coronary lesions at the
time of ICA (odds ratio: 0.79; 95% conﬁdence in-
terval: 0.56 to 1.11; p ¼ 0.17) (9). Collectively, nearly
two-thirds of patients undergoing nonemergent ICA
do not have anatomically obstructive CAD.
Recently, coronary computed tomography angiog-
raphy (CTA) has been offered as an anatomic alter-
native to stress imaging testing (1). Based on several
prospective multicenter studies, coronary CTA ex-
hibits high diagnostic performance for the identiﬁ-
cation and exclusion of anatomically obstructive
coronary stenosis compared with an ICA reference
standard. Coronary CTA ﬁndings are prognosticallyimportant and serve as effective guides toward
medical and invasive management. However, similar
to limitations of CFR that manifest a generally weak
association with ischemia, and further emphasizing
the complex relationship between stenosis and ﬂow,
coronary CTA has exhibited low speciﬁcity for iden-
tiﬁcation of ischemia-causing coronary stenosis (10).
Indeed, >50% of lesions considered anatomically
obstructive according to coronary CTA do not cause
ischemia. These ﬁndings are not singular to coronary
CTA but are observed uniformly for all anatomic
methods of coronary imaging, including ICA and
intravascular ultrasound.
INVASIVE FRACTIONAL FLOW RESERVE
Fractional ﬂow reserve (FFR) performed at the time of
ICA for combined anatomic–physiological evaluation
represents the current gold standard for determining
whether a coronary artery stenosis causes ischemia
(11). FFR is deﬁned as the ratio of maximal hyperemic
ﬂow to part of the myocardium in the presence of a
stenosis in the supplying epicardial artery to the
maximum hyperemic ﬂow to the same myocardial
territory in the hypothetical case in which the sup-
plying artery is normal. An FFR #0.80 (i.e., when the
distal coronary pressure is 80% of the aortic pressure
under conditions of maximal hyperemia) is
commonly accepted as the threshold below which a
lesion is considered ischemia causing. Deferral of
percutaneous coronary intervention (PCI) for vessels
with an FFR >0.80 is associated with improved clin-
ical outcomes and reduced costs compared with an
ICA alone–guided intervention (12). Conversely, cor-
onary revascularization in vessels with a measured
FFR #0.80 is associated with reduced risk of death,
myocardial infarction, or urgent revascularization
compared with an ICA alone–guided revascularization
or optimal medical therapy (OMT) alone (13,14). Based
on these and other data, current guidelines regarding
myocardial revascularization assign a Class IA
recommendation to FFR for the assessment of coro-
nary artery stenoses with a diameter reduction
ranging from 50% to 90% unless there is noninvasive
proof of ischemia (15).
CORONARY COMPUTED TOMOGRAPHY
ANGIOGRAPHY–DERIVED FRACTIONAL
FLOW RESERVE
Coronary computed tomography angiography–derived
fractional ﬂow reserve (FFRCT) is a novel noninvasive
approach for precise localization of ischemia-causing
coronary stenoses (Central Illustration). It applies
CENTRAL ILLUSTRATION Important Components for Calculation of Fractional Flow Reserve From CT (FFRCT)
Min, J.K. et al. J Am Coll Cardiol Img. 2015; 8(10):1209–22.
This ﬁgure demonstrates several of the important components of FFRCT. As can be seen, patient-speciﬁc geometry from coronary computed tomography allows for
accurate segmentation of coronary artery geometry. Each of these coronary artery segments undergoes mesh segmentation and the governing equations of ﬂuid
dynamics are solved for each of these meshes to calculate FFRCT within the entire vascular bed. Coupling arterial form with myocardial mass enables calculation of
relative myocardial blood ﬂow. FFRCT ¼ coronary computed tomography angiography–derived fractional ﬂow reserve.
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1211computational ﬂuid dynamics (CFD) to calculate
“3-vessel” FFR from typically acquired coronary
CTA images with no need for additional imaging
or vasodilators (16). The present review considers
the scientiﬁc principles and summarizes the prior
and ongoing clinical data informing the appropriate
use of FFRCT in daily practice.
STEPS TO CALCULATE FFRCT. The application of CFD
to calculate ﬂuid pressure, velocity, and ﬂow is
ubiquitous in engineering, including for the design of
automobiles and aircrafts (17). In these examples, the
ﬂuid dynamic to be evaluated is air, whereas in the
case of FFRCT, the ﬂuid dynamic to be evaluated is
blood. Any mathematical model of ﬂow, whether air
or blood, requires 3 elements: 1) description of theanatomic region of interest; 2) “boundary conditions”
to deﬁne physiological relationships between vari-
ables at the boundaries of the region; and 3) under-
standing the physical laws of ﬂuid ﬂow within the
region. Although the anatomic region of interest and
the boundary conditions are unique to each patient
and vessel, the governing equations describing the
physical laws of blood ﬂow, velocity, and pressure are
universal. Calculation of FFRCT requires 5 basic
steps: 1) creation of patient-speciﬁc anatomic models
from coronary CTA; 2) quantiﬁcation of the total
and vessel-speciﬁc baseline coronary artery ﬂow in
the hypothetical case in which the supplying vessels
are normal; 3) determination of the baseline myo-
cardial microcirculatory resistance; 4) quantiﬁcation
of the changes in coronary resistance with hyperemia;
FIGURE 1 Step-by-Step Method for Calculation of FFRCT
(A) Acquisition of coronary computed tomography angiography (CTA); (B) coronary artery segmentation to second- and third-order vessels; and (C) application of
subvoxel resolution techniques. In this example, a cross-section of a coronary artery shown with image intensity data (left) and image-gradient data (right) il-
lustrates typical coronary CTA reconstruction with increasingly improved image resolution (middle and bottom) demonstrating subvoxel resolution techniques. (D)
Discretization of mesh elements for calculation of computational ﬂuid dynamics (CFD) at millions of points in the coronary vascular bed. Note that the tetrahedral
vertices are reconstructed in 3 dimensions and are continuous even at the branch points to accurately calculate coronary computed tomography angiography–
derived fractional ﬂow reserve (FFRCT) at these areas commonly affected by plaque. Reduced order methods that do not use 3-dimensional analyses are less
accurate at these points. (E) Relationship of the location and size of coronary arteries to the left ventricular mass they subtend; (F) relationship of coronary vessel
caliber and ﬂow and resistance; (G) demonstration of reduced coronary resistance index at an adenosine dose of 140 mg/kg/min (Wilson et al. [25]); (H) Navier-
Stokes equations that govern the ﬂuid dynamics of blood (nonlinear partial differential equations related to mass conservation and momentum balance are solved);
and (I) example of a patient-speciﬁc FFRCT.
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1212and 5) application of CFD methods for calculation of
coronary ﬂow, pressure, and velocity at rest and
hyperemia. The step-by-step methods for calculating
FFRCT are illustrated in Figure 1.
Step 1. Creating Patient-Speciﬁc Anatomic Models From
Coronary CTA. Pressure losses along the coronary
artery are not just determined by the stenotic
segments but by the totality of coronary artery anat-
omy and blood ﬂow from the ostia to the distalmeasurement point (Figure 1A) (18). Lesion length,
serial lesions, and diffuse disease affect coronary ﬂow
and pressure. In addition, the perfusion territory
downstream of a coronary lesion affects the ﬂow
through that lesion and thus the pressure loss. Crea-
tion of patient-speciﬁc anatomic models of the coro-
nary arteries for FFRCT analysis therefore requires a
faithful representation of lumen dimensions for the
primary coronary arteries as well as the secondary
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1213and tertiary branches that deﬁne the perfusion terri-
tory downstream of a stenosis. These representations
are now reliably achieved with image acquisition
from $64-detector row coronary CTA (19).
Importantly, the advantages of the FFRCT tech-
nique compared with workstation-based algorithms
include: 1) improved spatial resolution; and 2) auto-
mated segmentation algorithms for whole-heart CFD
calculations (Figure 1B). Pertaining to the ﬁrst factor,
because the resistance of a coronary artery segment
can be approximated by using Poiseuille’s solution as
inversely related to vessel diameter to the fourth
power, limits in spatial resolution of coronary CTA
may introduce large errors in stenosis diameter and
exponentially larger errors in stenosis resistance,
pressure drop, and calculated FFRCT. Reconstruction
of image data with the smallest ﬁeld of view will
achieve an isotropic spatial resolution to w0.5 mm;
thus, even 1-voxel differences in a 2-mm vessel can
result in a 25% difference in diameter stenosis
severity. To address this outcome, FFRCT is facilitated
through advanced automated image segmentation
methods that use subvoxel resolution techniques
(Figure 1C). Image segmentation is the process of la-
beling voxels within a computed tomography (CT)
image to create a 3-dimensional reconstruction of the
heart and coronary arteries, whereas subvoxel reso-
lution techniques increase the spatial resolution of
the CT image (generally w0.5 to 0.8 mm) by subdi-
vision of voxels into different intensities based on
intensities in neighboring subvoxels. By these
methods, image information from a complete vessel
cross-section and neighboring cross-sections can be
used to estimate the diameter (or more generally, the
lumen boundary) of the vessel. Prior evidence, both
theoretical and empirical, has demonstrated
improved resolution by using subvoxel techniques
applied to CTA to w0.25 mm (20). Second, CFD cal-
culations of FFRCT necessitate discretization of a
ﬁnite set of 3-dimensional volumes within the coro-
nary artery image data (Figure 1D). Millions of tetra-
hedral “mesh” elements are generated within the
coronary artery image data, with increasing density at
the lateral boundaries of the coronary lumen, at
which the governing equations of blood ﬂow are
solved. To solve for these equations requires not only
automated generation of mesh elements but also
successful 3-dimensional representation of mesh
elements at all points in the coronary tree (including
bifurcations and trifurcations); this feature is not
available with commercially available workstations.
Step 2. Quantify Total and Vessel-Speciﬁc Coronary Artery
Flow. Allometric scaling laws serve as the foundation
for step 2 (quantiﬁcation of total and vessel-speciﬁccoronary artery ﬂow) and step 3 (determination of
myocardial microcirculatory resistance). Allometric
scaling laws refer to the relationships of an object size
to its anatomy or physiology, which can describe
relationship of deviation of an object from congruent
organization or isometry. Universally, allometric
scaling laws relating biologic variables to organism
size have the form Y ¼ Y0Mb, in which M is mass, b is
the scaling exponent, and Y0 is a normalization
constant.
For step 2, the allometric scaling law used is the
core scientiﬁc principle that baseline coronary artery
ﬂow is proportional to left ventricular myocardial
mass: QcorfMmyo0.75 (Figure 1E). This principle is used
with a patient’s blood pressure to compute total
baseline coronary artery resistance. Intuitively, this
method makes sense: increases in muscle mass
occur as a function of greater ﬂow. This premise
underscores the general approach to quantiﬁcation of
myocardial blood ﬂow per unit myocardial mass
according to positron emission tomography (e.g.,
millimeters per minute per gram), which denotes a
reliance of organ size to organ ﬂow. Experimentally,
this relationship was substantiated by Choy et al. (21),
who investigated scaling of myocardial ﬂow and mass
in a porcine model using microspheres to quantify
total coronary ﬂow. In this study, the investigators
observed a scaling exponent of 0.74  0.04, with an r2
value of 0.97. These data were conﬁrmed in several
different animal models, with scaling exponents
ranging between 0.74 and 0.776.
Step 3. Determine Myocardial Microcirculatory Resistance.
In this step, the core scientiﬁc principle used in the
FFRCT physiological model is that the microvascular
resistance is inversely proportional to vessel area, a
ﬁnding that is associated with increasing value as
blood traverses from the conduit epicardial vessels
into the intramyocardial pre-arterioles, arterioles,
and capillary beds. Assuming that epicardial coronary
stenoses are not ﬂow-limiting under resting condi-
tions (i.e., in the absence of rest angina), this princi-
ple implies that ﬂow through each branch of the
epicardial model created from coronary CTA data is
related to its area. These ﬁndings are based on a
continuous as well as a longitudinal adaptation of
coronary vessel caliber to ﬂow (22,23). Such adaptive
mechanisms occur during the progression of athero-
sclerotic disease through compensatory outward
remodeling of arteries to maintain coronary luminal
integrity. As disease progresses beyond a threshold at
which the artery can no longer outwardly remodel,
constrictive remodeling occurs and vessel lumen size
decreases, which also reduces ﬂow. Examples of the
principle relating ﬂow to arterial caliber can be
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1214observed in the dilated coronary artery size of
patients with hypertrophic and dilated cardiomyop-
athies (who have increased coronary ﬂow demand
from increased left ventricular myocardial mass) or in
peripheral arteriovenous ﬁstulas used for hemodial-
ysis, which may increase in size over time due to
increased ﬂow (24). Both of these illustrations are
examples of “form–function” relationships, wherein
the form (anatomy) of an object precisely informs its
function (physiology).
As shown in Figure 1F, the form–function relat-
ionship between ﬂow and vessel size enables deter-
mination of baseline ﬂow and resistance in a coronary
artery based on the size of the artery and the perfu-
sion territory downstream. The ability to isolate spe-
ciﬁc coronary vessels in relation to their downstream
microcirculatory resistance also enables determina-
tion of “myocardium at risk.” This is analogous to the
methods used by Gould et al. (6), who used similar
form–function principles to determine the fraction of
left ventricular mass at risk distal to a stenosis from
anatomic measurements of vessel sizes obtained from
arteriograms. In these studies, radiolabeled micro-
spheres quantifying ﬂow were related to vessel
lengths and diameters, with a curvilinear relationship
observed between coronary artery caliber and
dependent myocardial mass.
Step 4. Quantify Changes in Coronary Resistance at
Hyperemia. No vasodilator (e.g., adenosine, regade-
noson) is used in this step to quantify hyperemia;
rather, the hyperemic response is calculated compu-
tationally. In this step, the core scientiﬁc principle of
FFRCT is that microcirculatory resistance decreases
predictably at maximal hyperemia. This principle is
based on the data of Wilson et al. (25), who evaluated
the effects of increasing concentrations of adenosine
on total coronary resistance index. A maximum
reduction in the coronary resistance index (to 0.24 
0.01) was observed at an intravenous adenosine
dose of 140 mg/kg/min, beyond which no further
reduction could be observed. These ﬁndings have
informed the dose of adenosine needed to induce
hyperemia during stress testing and invasive FFR,
and they form the basis for the resistance calculations
in FFRCT.
Importantly, in the study by Wilson et al. (25),
the coefﬁcient of variation in patients with normal
CFR was w4%, which suggests a reliability and pre-
cision of hyperemia across a population of patients.
These data from “normal subjects” inform the FFRCT
model for computing the resistance to ﬂow of the
microvasculature downstream of each epicardial cor-
onary artery (Figure 1G). Notably, given the predict-
ability of reductions in resistance, dose-dependenttitration of resistance can be calculated for any given
FFRCT value. This method allows calculation of FFRCT
values across a physiologically realistic range (e.g.,
increasing levels of exercise); this may allow not only
for determination of which coronary stenoses cause
ischemia but also at precisely what level of increased
coronary ﬂow the ischemia is encountered.
Step 5. Apply CFD Methods for Calculation of
Coronary Flow, Pressure, and Velocity at Rest and
Hyperemia. Fundamental to the laws governing ﬂuid
dynamics are the Navier-Stokes equations, which
serve as the foundation for mathematical analyses
of coronary circulation behaviors. These equations
are conceptually simple, a statement of the con-
servation of mass and a generalization of Newton’s
second law (F ¼ ma) to a ﬂuid but are a mathe-
matically complex system of nonlinear partial dif-
ferential equations (Figure 1H). This complexity of
the Navier-Stokes equations of ﬂuid dynamics pre-
cluded their direct solution until the advent of the
digital computer and numerical methods. Further-
more, while general-purpose solvers of CFD are
available in the aerospace, automotive, and other
industries, solving for the equations of human
blood ﬂow in arteries poses unique challenges due
to the time- and spatially-varying properties of
coronary arteries and because ﬂow in coronary
arteries is intrinsically coupled to the heart on one
end and the microcirculation on the other.
Several methods exist to solve for the Navier-
Stokes equations for FFRCT, including lumped-
parameter models, 1-dimensional wave models,
and 3-dimensional models. In the lumped-
parameter method, spatially varying properties of
arteries are lumped into large discrete components
(26). For example, the ﬂuid resistance along the
length of a vessel is represented as a single resistive
element with parameter values derived by using an
idealized solution assuming steady, axisymmetric,
unidirectional ﬂow in a circular cylindrical model
of a blood vessel. Although the simplicity of
lumped-parameter models enables whole body
models of the circulation with general computa-
tional ease, it is invalid in diseased segments in
which blood ﬂow is not steady, axisymmetric, or
unidirectional and the vessel segments are not cir-
cular cylinders. FFRCT has been explored in inves-
tigational software programs by using 1-dimensional
wave models, which are derived by averaging the
Navier-Stokes equations over a vessel cross-section
assuming the axial velocity proﬁle is the same at
all locations along the vessel and in all vessels and
that pressure is constant over the vessel cross-
section (27). Although the assumptions made for
TABLE 1 Patient-Based Diagnostic Performance of Noninvasive
Imaging Versus Fractional Flow Reserve (40)
N Sensitivity, PLR Speciﬁcity, NLR
SPECT 533 74%, 3.13 79%, 0.39
Echo 177 69%, 3.68 84%, 0.42
CMR 798 89%, 6.29 87%, 0.14
PET 224 84%, 6.53 87%, 0.14
CT 316 88%, 3.79 80%, 0.12
CT ¼ computed tomography; CMR ¼ cardiac magnetic resonance; NLR ¼ negative
likelihood ratio; PET ¼ positron emission tomography; PLR ¼ positive likelihood
ratio; SPECT ¼ single-photon emission computed tomography.
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1215the 1-dimensional models are reasonable for
computing ﬂow and pressure in large, straight, and
generally healthy segments, they are invalid in
segments that are small, near side branches or bi-
furcations, or with complex nonuniform luminal
compromise, as often occur from coronary
atheroma. Thus, FFRCT is calculated by using 3-
dimensional models of blood ﬂow, which offer the
advantage of direct representation of the true
geometry of the circulation, the full complexity of
3-dimensional pulsatile or unsteady ﬂow (including
turbulence), and inclusion of complex material
models for blood or blood vessels (Figure 1I).
Overall, the calculation of FFRCT can take up to 8 h,
but most calculations can be done within a few hours.
Future iterations incorporating automated segmen-
tation methods and machine-learning techniques
offer hope that FFRCT can be calculated within
minutes.
CLINICAL DATA FOR FFRCT
In a landmark paper, Fryback and Thornbury (28)
contextualized technology evaluation for diagnostic
imaging, describing a hierarchical model of efﬁcacy.
This model describes the ideal evidence base
necessary for proof of the value of a diagnostic im-
aging test and addresses factors related to diagnostic
accuracy and technical quality, diagnostic and ther-
apeutic impact, and patient and societal outcomes.
Since its initial demonstration of feasibility of use in
humans in 2011, a signiﬁcant body of clinical evi-
dence for FFRCT has developed to evaluate its diag-
nostic performance with an invasive FFR reference
standard. At present, 11 multicenter clinical trials
of FFRCT have been completed (n ¼ 5), are ongoing
(n ¼ 4), or are being actively designed (n ¼ 2)
(Tables 1 to 3). We herein describe the available and
ongoing clinical data for FFRCT that address these
issues, constraining our discussion to results derived
from or informing the design of prospective multi-
center trials of FFRCT.
DIAGNOSTIC ACCURACY AND REPRODUCIBILITY OF
FFRCT. The diagnostic performance of FFRCT has
been evaluated in 3 prospective, multicenter clinical
trials using measured FFR as the reference standard
and blinded core laboratory controls: DISCOVER-
FLOW (Diagnosis of Ischemia-Causing Stenoses
Obtained Via Noninvasive Fractional Flow Reserve),
DeFACTO (Determination of Fractional Flow Reserve
by Anatomic Computed Tomographic Angiography),
and NXT (Analysis of Coronary Blood Flow Using
CT Angiography: Next Steps). These 3 studies
comprise a total of 609 patients and 1,050 vessels.The ﬁrst clinical trial to evaluate FFRCT technology
was the DISCOVER-FLOW trial, which included 103
patients and 159 vessels from 4 sites in the United
States, Europe, and Asia (29). FFRCT improved diag-
nostic accuracy by 42% compared with coronary CTA
(84% vs. 59%), which occurred as a result of a 2-fold
improvement in speciﬁcity (84% vs. 40%) with no
changes in sensitivity (87% vs. 91%). FFRCT exhibited
signiﬁcant improvement in discrimination of ischemia
with an increase in the area under the receiver-
operating characteristic curve (AUC) compared with
coronary CTA (0.90 vs. 0.75; p < 0.001). The
DISCOVER-FLOW trial was conducted with the ﬁrst
generation (version 1.0) of FFRCT algorithms (16), and
the quality of the image data was ensured by excluding
coronary CTA scans that were deemed nonevaluable
by the FFRCT core laboratory.
The DeFACTO study comprised 252 patients at 17
centers with 407 vessels directly interrogated by us-
ing FFR (30). Parallel to the DISCOVER-FLOW ﬁnd-
ings, the diagnostic accuracy of FFRCT was higher
than CT stenosis (73% vs. 64%), which occurred as a
function of improved speciﬁcity (54% vs. 42%) and
comparable sensitivity (90% vs. 84%) to coronary
CTA. FFRCT demonstrated superior per-patient and
per-vessel discrimination of ischemia compared with
coronary CTA, with AUCs of 0.81 versus 0.68 (p <
0.001) and 0.81 versus 0.75 (p < 0.001), respectively.
The DeFACTO trial was conducted with second-
generation (version 1.2) FFRCT algorithms, and CT
image quality for inclusion in the study was deter-
mined by an external CT core laboratory.
The most recently performed NXT trial investi-
gated the diagnostic performance of FFRCT in 254
patients and 484 vessels (31). The per-vessel accuracy
and speciﬁcity to identify arteries that caused
myocardial ischemia were signiﬁcantly higher for
FFRCT (86% and 86%) than for coronary CTA (65% and
60%) (p < 0.001). Sensitivity was unchanged at 83%
for coronary CTA and 84% for FFRCT. FFRCT also
demonstrated superior per-patient and per-vessel
TABLE 2 Completed Multicenter Trials or Registries of FFRCT
Study Name (Ref. #) NCT n Study Findings
Per-Vessel Per-Patient
Sensitivity,
PPV
Speciﬁcity,
NPV
Sensitivity,
PPV
Speciﬁcity,
NPV
DISCOVER-FLOW (29) NL 103 Diagnostic performance
trial evaluating ﬁrst version
of FFRCT (version 1.0)
88%, 74% 82%, 92% 93%, 85% 81%, 91%
DeFACTO (30) NCT01233518 252 Diagnostic performance trial
evaluating older version
of FFRCT (version 1.2)
83%, NR 78%, NR 90%, 67% 54%, 84%
NXT (31) NCT01757678 254 Diagnostic performance
trial evaluating latest
generation version of
FFRCT (version 1.4)
84%, 61% 86%, 95% 86%, 65% 79%, 93%
RIPCORD-FFRCT (35) NL 200 Evaluation of the diagnostic
impact of FFRCT to guide
medical versus invasive
therapies
 36% change in management based on FFRCT
 23% increase in OMT alone
 5% decrease in planned PCI (18% change
in target vessel for PCI)
 0.5% increase in planned CABG
PLATFORM (41) NCT01943903 580 Sequential longitudinal
cohort study demonstrating
61% reduction in
CATH normalcy for
FFRCT-guided vs.
coronary CTA-guided care
CABG ¼ coronary artery bypass graft; DeFACTO ¼ Determination of Fractional Flow Reserve by Anatomic Computed Tomographic Angiography; DISCOVER-FLOW ¼ Diagnosis
of Ischemia-Causing Stenoses Obtained Via Noninvasive Fractional Flow Reserve; FFRCT ¼ coronary computed tomography angiography–derived fractional ﬂow reserve; NCT ¼
National Clinical Trial; NL ¼ not listed; NPV ¼ negative predictive value; NR ¼ not reported; NXT ¼ Analysis of Coronary Blood Flow Using CT Angiography: Next Steps; OMT ¼
optimal medical therapy; PCI ¼ percutaneous coronary intervention; PLATFORM ¼ Prospective LongitudinAl Trial of FFRct: Outcome and Resource IMpacts; PPV ¼ positive
predictive value.
TABLE 3 Prospectiv
Trial Ongoing
CREDENCE
PERFECTION
DECIDE-Gold
CONSERVE
ADVANCE
Being discussed
FAME-FFRCT
ADVANCE ¼ Assessing Di
Computed Tomographic A
Raphic Evaluation of Athe
angiography; DECIDE-Gold
Invasive and Invasive Tech
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1216discrimination of ischemia compared with coronary
CTA, with AUCs of 0.90 versus 0.81 (p < 0.001) and
0.93 versus 0.79 (p < 0.0001), respectively. The latest
generation of FFRCT (version 1.4) software was used;e Multicenter Trials or Registries of FFRCT
NCT N Study Findings/Objectives
NCT02173275 618 Direct head-to-head comparison of
coronary CTA plus FFRCT versus
myocardial perfusion imaging
by SPECT or PET
NYL NYL Comparison of FFRCT versus
single-energy CT rest/stress
perfusion imaging
NCT02178904 156 Comparison of FFRCT versus
dual-energy CT rest/stress
perfusion imaging
NCT01810198 1500 Evaluation of FFRCT as a “gatekeeper”
to invasive coronary angiography
(secondary aim)
NCT02499679 ND Prospective longitudinal registry
to evaluate prognostic
implications of FFRCT
NYL ND Randomized controlled trial
evaluating FFRCT-guided strategies
versus standard of care
agnostic Value of Non-invasive FFRCT in Coronary Care; CONSERVE ¼ Coronary
ngiography for Selective Cardiac Catheterization; CREDENCE ¼ Computed Tomog-
rosclerotic DEtermiNants of Myocardial IsChEmia; CTA ¼ computed tomography
¼ Dual Energy CT for Ischemia Determination Compared to “Gold Standard” Non-
niques; NYL ¼ not yet listed; other abbreviations as in Tables 1 and 2.it incorporated reﬁnements in image-processing
methods and physiological modeling, using informa-
tion derived from study patients of earlier trials.
The reproducibility of FFR and FFRCT were evalu-
ated in 28 patients (58 vessels) in a substudy of NXT
(32). FFR measurements were performed twice
with removal of the pressure wire and cessation of
adenosine between measurements. FFRCT was then
performed twice for each patient by 2 independent
blinded analysts at different time points. The coefﬁ-
cient of variation of FFRCT was 3.4% (95% conﬁdence
interval: 1.4 to 4.6) versus 2.7% (95% conﬁdence in-
terval: 1.8 to 3.3) for FFR. As with any noninvasive
test compared with invasive FFR, there were differ-
ences. The average errors associated with FFRCT
versus FFR differed by FFRCT value and were highest
for values #0.70 and lowest for values >0.90, sup-
porting its high negative predictive value. According
to FFRCT value, they were: #0.70, –0.06  0.11; 0.71 to
0.75, –0.03  0.13; 0.76 to 0.80, –0.03  0.08; 0.81 to
0.85, –0.05  0.07; 0.86 to 0.90, –0.03  0.06; and
0.91 to 1.00, –0.01  0.05 (29–31).
The continually improving diagnostic performance
of FFRCT is a “moving target.” Even among the 3
trials performed to date (29–31), newer generation
iterations were sequentially evaluated. Currently,
machine learning (a form of artiﬁcial intelligence) is
being applied to FFRCT to train automated image
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 8 , N O . 1 0 , 2 0 1 5 Min et al.
O C T O B E R 2 0 1 5 : 1 2 0 9 – 2 2 Noninvasive Fractional Flow Reserve From CT
1217analysis algorithms to robustly extract anatomic
models accurately from coronary CTA data. These
methods can also be used to reﬁne the ability of
FFRCT to more precisely localize ischemia-causing
coronary lesions by identifying image-based re-
lationships that cannot be determined with the use of
traditional regression methods. By their nature, these
machine-learning methods will continually iterate
data-driven predictions and improve FFRCT algo-
rithms over time with less need for human input. In
addition, machine-learning methods can be used to
compute the sensitivity of FFRCT computations to
geometric uncertainty arising from variations in im-
age quality or physiological variability, which can be
used to compute conﬁdence intervals to aid clinical
decision making (33).
SELECT SUBPOPULATIONS AND FFRCT DIAGNOSTIC
PERFORMANCE. FFRCT was evaluated for patients
with intermediate stenosis severity (30% to 70%)
in the DeFACTO study, in which a >2-fold increase
in sensitivity was observed for FFRCT over coronary
CTA stenosis alone (82% vs. 37%), with no
compromise in speciﬁcity (Figure 2C) (34). In the
NXT study, improved speciﬁcity of FFRCT compared
with coronary CTA was observed (79% vs. 32%;
p < 0.0001), with no differences in sensitivity
(85% vs. 93%).
The diagnostic accuracy of FFRCT and coronary
CTA was compared for ischemia evaluation in pa-
tients with severely elevated coronary artery calcium
scores >400 (Figure 2A). In the NXT trial, per-patient
accuracy and speciﬁcity were higher for FFRCT
than for coronary CTA (75% vs. 44% and 69% vs. 23%
[both p < 0.0001]), with no sacriﬁce in sensitivity.
These ﬁndings were in accordance with those
observed in the DeFACTO trial.
To date, no FFRCT study has been reported that
examines its diagnostic performance in a myriad
of patient cohorts, which may display important
differences in microvascular resistance and, hence,
differing accuracies of FFRCT. These cohorts include
those with left ventricular hypertrophy, diabetic
patients (with increasedﬁbrosis), or patientswith prior
myocardial infarction or post-revascularization.
IMAGE ACQUISITION PROTOCOLS, CORONARY
CTA IMAGING ARTIFACTS, AND FFRCT PERFORMANCE.
Consistent among the DISCOVER-FLOW, DeFACTO,
and NXT trials was an observed improvement in
overall diagnostic accuracy that stemmed from a
signiﬁcant reduction in “false-positive” coronary CTA
studies, wherein a stenosis was considered high-
grade, but lesion-speciﬁc ischemia was not present.
However, there were also numerous ﬁndings related
to image acquisition protocols, image quality, andimaging artifacts. Although no special imaging pro-
tocols are required for FFRCT, adherence to Society
of Cardiovascular Computed Tomography guidelines
is recommended to maintain high image quality
for accurate results. These protocols include the
recommended use of pre-coronary CTA nitrates
and beta-blockers for maximal visualization of the
coronary artery lumen and minimization of motion
artifact.
Noncompliance with the Society of Cardiovascular
Computed Tomography recommendations regarding
coronary CTA imaging protocols is associated
with impaired diagnostic performance of FFRCT. In
the DeFACTO trial, administration of a beta-blocker
and nitroglycerin increased FFRCT speciﬁcity
(66.0% vs. 51.0% [p ¼ 0.03] and 75.0% vs. 54.0%
[p ¼ 0.013]), with a lower systematic bias observed
after beta-blocker administration (–0.084 vs. –0.048;
p ¼ 0.008). The per-vessel speciﬁcity improved
from 54% for patients who received sublingual nitrates
>30min before the acquisition of coronary CTA data to
75% for patients administered sublingual nitrates #30
min before the coronary CTA acquisition.
In the DeFACTO and NXT clinical trials, 11% and
13% of studies, respectively, were rejected because of
low image quality. Low image quality can occur from
common coronary CTA artifacts, including misregis-
tration, coronary motion, or poor opaciﬁcation of the
coronary arteries. In the DeFACTO study, coronary
CTA misalignment artifacts resulted in impaired
sensitivity of FFRCT compared with images without
misalignment artifacts (43.0% vs. 86.0%; p ¼ 0.001),
with resultant reductions in overall accuracy (56.0%
vs. 71.0%; p ¼ 0.03). In both the DeFACTO and NXT
studies, FFRCT accuracy was unaffected by motion or
increasing coronary calcium score.
To date, FFRCT studies have evaluated its diag-
nostic power for ischemia by using an invasive FFR
standard compared with coronary CTA alone or other
coronary CTA–based approaches (e.g., transluminal
attenuation gradient or plaque characterization),
without comparative evaluation versus stress imag-
ing tests. Three ongoing clinical trials are testing
FFRCT against other methods for MPI. The CREDENCE
(Computed TomogRaphic Evaluation of Atheroscle-
rotic DEtermiNants of Myocardial IsChEmia) trial is a
20-site study of 618 patients undergoing coronary
CTA plus FFRCT, MPI SPECT, positron emission to-
mography or cardiac magnetic resonance, and ICA
with FFR (NCT02173275). In the ﬁrst 309 patients,
coronary CTA and MPI scores will be developed
that account for the totality of information imparted
by coronary CTA and stress testing. These will
include: severity, location, extent, and distribution of
FIGURE 2 Clinical Examples of FFRCT
(A) Coronary CTA demonstrating severe calciﬁcations of the left main, left anterior descending (LAD), and left circumﬂex (LCx) arteries (left).
FFRCT model demonstrating coronary ischemia of the LAD, with a value of 0.74 (middle). Invasive coronary angiography (ICA) demonstrating
intermediate stenosis severity that causes ischemia according to FFR, with a value of 0.71 (right). (B) Coronary CTA demonstrating diffuse
coronary artery disease (CAD) from multiple tandem lesions in the LAD (left). FFRCT demonstrating coronary ischemia of the LAD, with a value
of 0.70 (middle). ICA demonstrating diffuse luminal irregularities that result in ischemia according to FFR, with a value of 0.74 (right). (C)
Coronary CTA demonstrating an intermediate stenosis of the LAD (left). FFRCT demonstrating coronary ischemia of the LAD, with a value of
0.78 (middle). ICA demonstrating intermediate stenosis severity that causes ischemia according to FFR, with a value of 0.78 (right). (D)
Coronary CTA demonstrating a small left main and LAD with mild diffuse calciﬁc plaque (left). Despite the absence of high-grade stenoses,
ischemia is noted by using FFRCT, with a value of 0.75 (middle). ICA demonstrating similar concordance with a value of 0.81 (right). (E)
Example of “virtual stenting.” In the ﬁrst pane, an FFRCT model demonstrates coronary ischemia of the obtuse marginal branch of the left
circumﬂex artery, with a value of 0.61. In the second pane, ICA and invasive FFR conﬁrm a high-grade stenosis and ischemia, with an FFR value
of 0.52. In the third pane, a virtual stent is placed with predicted resolution of the ischemia by FFRCT, with a value of 0.83. In the fourth pane, a
post–percutaneous coronary intervention FFR demonstrates resolution of ischemia with, a value of 0.88. QCA ¼ quantitative coronary
angiography; other abbreviations as in Figure 1.
Continued on the next page
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1218coronary stenoses; atherosclerotic plaque volume and
characteristics; and FFRCT. For stress imaging testing,
these data will include not only the presence of
perfusion defects but also their location, extent,
severity, and reversibility; also included were ancil-
lary imaging (e.g., transient ischemic dilation), exer-
cise treadmill, and electrocardiographic ﬁndings.The scores will be subsequently validated and
compared with each other in the next 309 patients.
These data should deﬁnitively determine which
noninvasive diagnostic tests are optimal for diagnosis
of lesion-speciﬁc ischemia with a robust derivation/
validation design. Two additional multicenter trials
(PERFECTION and DECIDE-Gold [Dual Energy CT
FIGURE 2 Continued
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1219for Ischemia Determination Compared to “Gold
Standard” Non-Invasive and Invasive Techniques]
[NCT02178904]) will compare the diagnostic perfor-
mance of FFRCT against single-energy and dual-
energy CT perfusion stress testing, respectively,
using FFR as a reference standard.
DIAGNOSTIC AND THERAPEUTIC IMPACT
An emerging body of evidence suggests that the use of
FFRCT may affect patient-speciﬁc diagnostic ap-
proaches as well as therapeutic options. In the RIP-
CORD (Does Routine Pressure Wire Assessment
Inﬂuence Management Strategy at Coronary Angiog-
raphy for Diagnosis of Chest Pain?) study, Curzen et al.
(35) evaluated 200 consecutive patients from the NXT
trial to determine whether the addition of noninvasive
FFRCT to coronary CTA in patients with stable chest
pain would lead to: 1) changes in the interpretation of
lesion-speciﬁc “signiﬁcance”; or 2) changes in the
management plan (36). In this study, 3 cardiologists
reviewed the coronary CTA images and their site-
recorded interpretations, and by consensus decidedon a management plan consisting of OMT alone, PCI
plus OMT, coronary artery bypass graft (CABG) plus
OMT, or deferred decision until after invasive FFR was
performed. The interventionalists were then provided
the FFRCT data and reported whether their manage-
ment plan would remain the same or change. Notably,
77% (65 of 84) and 46% (38 of 83) of lesions with 51%
to 70% and 71% to 90% stenosis, respectively, were
found not to cause ischemia according to FFRCT.
These ﬁndings were associated with an overall
change in management in 36% of patients (n ¼ 72),
with a 23% increase in planned use of OMT alone, a
5% decrease in planned PCI, and a 0.5% increase in
planned CABG. Among patients assigned to PCI,
18% (16 of 87) saw a change in target vessels based
on the FFRCT result.
PATIENT AND SOCIETAL OUTCOMES
To evaluate the cost efﬁciency (or minimization of
health care costs with equivalent or improved clinical
outcomes) of FFRCT-based strategies, Hlatky et al. (37)
constructed a decision analysis comparing 5 clinical
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1220strategies: 1) ICA with stenosis-based PCI; 2) ICA with
FFR-guided PCI; 3) coronary CTA followed by ICA and
stenosis-based PCI; 4) coronary CTA followed by ICA
and FFR-guided PCI; and 5) coronary CTA–FFRCT fol-
lowed by FFRCT-guided PCI (37). The projected initial
management costs were highest for ICA with stenosis-
based PCI and lowest for the coronary CTA–FFRCT fol-
lowed by FFRCT -guided PCI ($10,702 vs. $7,674,
respectively), an economic beneﬁt associated with a
12% reduction in adverse cardiovascular events at 1
year.
Such ﬁndings informed the design of the
multicenter, pragmatic, comparative effectiveness
PLATFORM (Prospective LongitudinAl Trial of FFRct:
Outcome and Resource IMpacts) trial, a 584-patient,
prospective, controlled utility trial evaluating pa-
tients with an intermediate likelihood of CAD (upda-
ted Diamond-Forrester risk scores 20% to 80%) who
are being referred for noninvasive evaluation (ﬁrst
cohort) or ICA (second cohort) (NCT01943903) (36).
Longitudinally, sites evaluated patients by using
standard of care approaches (ﬁrst phase) and then an
approach based on coronary CTA–FFRCT (second
phase). The primary endpoint of PLATFORM was the
rates of ICA without anatomically “obstructive” CAD,
with important secondary endpoints related to costs,
resource utilization, quality of life, and radiation
exposure. Results are anticipated shortly.
Each of the aforementioned trials evaluates radia-
tion exposure as a secondary endpoint, given con-
cerns regarding the safety of the different diagnostic
testing approaches. This principle of safety is well
described and an important goal to any diagnostic
test but is largely irrelevant to the discussion of
FFRCT. FFRCT requires no additional imaging and
hence no additional radiation or intervention beyond
what is already acquired through coronary CTA.
FUTURE LARGE-SCALE FFRCT
CLINICAL STUDIES
Given the recent introduction of FFRCT, its long-term
prognostic utility and its incremental value for risk
stratiﬁcation beyond coronary CTA ﬁndings are
unknown. ADVANCE (Assessing Diagnostic Value
of Non-invasive FFRCT in Coronary Care) is a multi-
center registry that will evaluate the clinical and eco-
nomic impacts of FFRCT as well as its downstream
impact and net reclassiﬁcation of subjects with
abnormal FFRCT for adverse clinical outcomes
(NCT02499679). Furthermore, a FAME-type random-
ized controlled trial is being discussed, which will
evaluate the efﬁcacy of an FFRCT-guided strategy to
improve clinical outcomes beyond a stenosis-guidedstrategy in patients referred for invasive or noninva-
sive ischemia testing.
CONTEXTUALIZATION OF FFRCT IN
CAD IMAGING
In recent years, there has been discussion regarding
the strengths and limitations of diagnostic testing for
CAD. Prior large-scale registry data for coronary CTA
and stress testing have focused largely on the diag-
nostic and prognostic utility of imaging ﬁndings, with
relatively little intertest comparisons. Indeed, only in
the last several months have we witnessed the pre-
sentation of the ﬁrst 2 large-scale, randomized
controlled trials (PROMISE [Prospective Multicenter
Imaging Study for Evaluation of Chest Pain] and
SCOT-Heart [Scottish Computed Tomography of the
Heart]) that directly compared functional versus
anatomic testing strategies for downstream clinical
outcomes. Both of these studies shared generally
similar ﬁndings (38,39). With no signiﬁcant differ-
ences noted in “hard” adverse clinical events be-
tween coronary CTA and stress testing, coronary CTA
was associated with reduced ICA normalcy rates
(fewer “false-positive” studies), greater diagnostic
certainty, and increased use of primary prevention
medications. Coronary CTA was also associated with
an increase in coronary revascularization rates
(particularly of surgical CABG), with a trend toward
reduced death and myocardial infarction at 1 year.
These data lend support to the clinical use of coro-
nary CTA for evaluation of patients with suspected
CAD. The coupling of FFRCT to coronary CTA now
offers an additional pathway for diagnosis of CAD,
thus expanding the anatomic capabilities offered by
coronary CTA to include physiological information
that allows for direct interrogation of the functional
signiﬁcance of any or all coronary artery lesions.
In the context of the recent approval of FFRCT by
the U.S. Food and Drug Administration for routine
clinical use for patients without known CAD, it is
germane to consider the questions necessary to
resolve when faced with a symptomatic patient with
suspected CAD and to also evaluate FFRCT in this
context. Given the adverse prognosis that exists for
even mild forms of coronary atherosclerosis, a
sequential approach to CAD diagnostic evaluation
sensibly begins with determination of whether any
CAD exists (high sensitivity), whether any revascu-
larizable coronary stenoses exist without over-
estimation of severity (high speciﬁcity), and whether
visualized coronary stenoses impair coronary ﬂow.
The available clinical evidence supports FFRCT as
fulﬁlling these criteria.
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FFRCT to impaired image quality, several additional
limitations of this method should be considered. At
present, little is known regarding the impact of
FFRCT as a function of angina typicality. As such,
whether typical angina can be discounted based on
an FFRCT <0.80 (or vice versa) is unknown. The
ﬁeld should be careful to examine this noninvasive
test in the context of clinical information. These
include not only the symptom typicality of pre-
senting patients but also stress imaging results.
Only future studies examining the relationship of
FFRCT to these data will reveal its precise role in
clinical practice.
In addition to these diagnostic features, FFRCT has
been shown capable of identifying ischemia which
stem from coronary lesions that do not meet con-
ventional deﬁnitions of “angiographically severe”
(i.e., intermediate stenoses, diffuse atherosclerosis)
(Figure 2B) and small vessels demonstrating inade-
quate vasodilation. Finally, FFRCT has the potential to
predict the therapeutic beneﬁt of coronary revascu-
larization by “virtual stenting” or even the relative
efﬁcacy of revascularization strategy (Figure 2E). As
an example of the latter, multivessel virtual stenting
may be compared with “virtual bypass surgery” byusing FFRCT to determine which method maximally
reduces ischemia (Figure 2D). Whether these methods
can more effectively reduce ischemia or improve
clinical outcomes remains unknown but is currently
being evaluated.
CONCLUSIONS
FFRCT is a novel method that uses CFD for deter-
mining the hemodynamic signiﬁcance of coronary
artery lesions by using patient-speciﬁc data extracted
from typically acquired coronary CTA. Prior multi-
center trials have shown a generally high diagnostic
performance of FFRCT. Ongoing trials comparing
the diagnostic performance of FFRCT versus stress
imaging methods—as well as the clinical support
and cost-effectiveness of FFRCT-based strategies
compared with the usual care strategies—will inform
its most appropriate use in clinical practice.
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